Dorian Therapeutics is a pre-clinical Silicon Valley biotech focused on developing treatments that counteract aging in degenerative diseases and during cellular therapy. Dorian’s innovative therapeutics, called senoblockers, inhibit the process of cellular senescence while activating the regenerative capacity of tissues. Founded by two Stanford Medical School alumni, the company is backed by several venture capital firms including Blumberg Capital, The Longevity Fund, and Pacific8, as well as top biotech incubators including Y Combinator and StartX.

See news about Dorian Therapeutics here.